| Naslov: | Toward precision medicine : molecular biomarkers of response to tofacitinib in inflammatory bowel disease |
|---|
| Avtorji: | ID Bizjak, Anja (Avtor)
ID Gole, Boris (Avtor)
ID Jezernik, Gregor (Avtor)
ID Potočnik, Uroš (Avtor)
ID Gorenjak, Mario (Avtor) |
|---|
| Datoteke: |  RAZ_Bizjak_Anja_2025.pdf (881,71 KB)
MD5: 42723389EB621E8FF49168B05CD88085
 https://doi.org/10.3390/genes16080908
https://www.mdpi.com/2073-4425/16/8/908
|
|---|
| Jezik: | Angleški jezik |
|---|
| Vrsta gradiva: | Znanstveno delo |
|---|
| Tipologija: | 1.02 - Pregledni znanstveni članek |
|---|
| Organizacija: | MF - Medicinska fakulteta
|
|---|
| Opis: | Ulcerative colitis (UC), a subtype of inflammatory bowel disease (IBD), is a chronic, relapsing inflammatory condition that significantly impairs the patient’s quality of life. While biologics have transformed disease management, a substantial number of patients remain unresponsive or lose efficacy over time. Tofacitinib (TOFA), an oral Janus kinase (JAK) inhibitor, introduces a novel therapeutic class of small-molecule drugs with a unique oral administration route, offering enhanced patient convenience and broader accessibility compared to parenterally administered biologics. As the first oral treatment approved for moderate to severe UC in years, TOFA acts by modulating the JAK/STAT pathway, influencing critical inflammatory mediators such as IL-6, IL-17, and IFN-γ. However, response rates are variable and appear dose-dependent, with up to 60% of patients showing inadequate therapeutic outcomes. This review represents the first comprehensive synthesis focused specifically on biomarkers of TOFA response in UC. Drawing on multi-omics data—epigenomics, transcriptomics, proteomics, and cellular profiling, we highlight emerging predictors of responsiveness, including CpG methylation signatures (e.g., LRPAP1 and FGFR2), transcriptomic regulators (e.g., REG3A and CLDN3), immune and epithelial cell shifts, and the cationic transporter MATE1. TOFA demonstrates a dual mechanism by modulating immune responses while supporting epithelial barrier restoration. Despite being promising, TOFA’s dose-dependent efficacy and interpatient variability underscore the critical need for non-invasive, predictive biomarkers to guide personalized treatment. As the first review of its kind, this work establishes a basis for precision medicine approaches to optimize the clinical utility of TOFA in UC management. |
|---|
| Ključne besede: | inflammatory bowel disease, ulcerative colitis, genomics, tofacitinib, transcriptomics, proteomics |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Poslano v recenzijo: | 27.07.2025 |
|---|
| Datum sprejetja članka: | 10.07.2025 |
|---|
| Datum objave: | 29.07.2025 |
|---|
| Založnik: | MDPI |
|---|
| Leto izida: | 2025 |
|---|
| Št. strani: | Str. [1]-23 |
|---|
| Številčenje: | Letn. 16, Št. 8 |
|---|
| PID: | 20.500.12556/DKUM-94341  |
|---|
| UDK: | 616.34-002 |
|---|
| COBISS.SI-ID: | 245399043 |
|---|
| DOI: | 10.3390/genes16080908 |
|---|
| ISSN pri članku: | 2073-4425 |
|---|
| Datum objave v DKUM: | 18.08.2025 |
|---|
| Število ogledov: | 294 |
|---|
| Število prenosov: | 19 |
|---|
| Metapodatki: |    |
|---|
| Področja: | Ostalo
|
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Skupna ocena: | (0 glasov) |
|---|
| Vaša ocena: | Ocenjevanje je dovoljeno samo prijavljenim uporabnikom. |
|---|
| Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
